End-Stage Renal Failure Patients Requiring Renal Replacement Therapy in the Intensive Care Unit: Incidence, Clinical Features, and Outcome

2003 ◽  
Vol 21 (2) ◽  
pp. 170-175 ◽  
Author(s):  
Shigehiko Uchino ◽  
Hiroshi Morimatsu ◽  
Rinaldo Bellomo ◽  
William Silvester ◽  
Louise Cole
Keyword(s):  
Intensive Care Unit ◽  
Renal Failure ◽  
Intensive Care ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Clinical Features ◽  
End Stage Renal Failure ◽  
End Stage

scholarly journals Successful Renal Replacement Therapy for a Patient with Severe Hemophilia after Surgical Treatment of Intracranial Hemorrhage and Hydrocephalus

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Noriko Kato ◽  
Masami Chin-Kanasaki ◽  
Yuki Tanaka ◽  
Mako Yasuda ◽  
Yukiyo Yokomaku ◽  
...  
Keyword(s):  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Hemophilia A ◽  
Severe Hemophilia ◽  
End Stage Renal Failure ◽  
Japanese Male ◽  
Old Japanese ◽  
End Stage

A 21-year-old Japanese male with severe hemophilia A was developed end-stage renal failure. He was placed on combination therapy with peritoneal dialysis (PD) and hemodialysis (HD). Eight months later, he developed a hypertensive cerebral hemorrhage. After emergency surgery, he was managed with PD without HD to avoid cerebral edema. One month later, his renal replacement therapy was switched to HD (three times a week) from PD, since a ventriculoperitoneal shunt catheter was placed to treat his hydrocephalus. HD could be performed safety without anticoagulant agents on condition that factor VIII is given after every HD.

scholarly journals Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration

2010 ◽  
Vol 54 (6) ◽  
pp. 2596-2602 ◽  
Author(s):  
Verena Hafner ◽  
David Czock ◽  
Jürgen Burhenne ◽  
Klaus-Dieter Riedel ◽  
Jürgen Bommer ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Half Life ◽  
Repeated Measures ◽  
High Flux ◽  
Polysulfone Membrane ◽  
End Stage Renal Failure ◽  
Beta Cyclodextrin ◽  
End Stage

ABSTRACT Sulfobutylether-beta-cyclodextrin (SBECD), a large cyclic oligosaccharide that is used to solubilize voriconazole (VRC) for intravenous administration, is eliminated mainly by renal excretion. The pharmacokinetics of SBECD and voriconazole in patients undergoing extracorporeal renal replacement therapies are not well defined. We performed a three-period randomized crossover study of 15 patients with end-stage renal failure during 6-hour treatment with Genius dialysis, standard hemodialysis, or hemodiafiltration using a high-flux polysulfone membrane. At the start of renal replacement therapy, the patients received a single 2-h infusion of voriconazole (4 mg per kg of body weight) solubilized with SBECD. SBECD, voriconazole, and voriconazole-N-oxide concentrations were quantified in plasma and dialysate samples by high-performance liquid chromatography (HPLC) and by HPLC coupled to tandem mass spectrometry (LC-MS-MS) and analyzed by noncompartmental methods. Nonparametric repeated-measures analysis of variance (ANOVA) was used to analyze differences between treatment phases. SBECD and voriconazole recoveries in dialysate samples were 67% and 10% of the administered doses. SBECD concentrations declined with a half-life ranging from 2.6 ± 0.6 h (Genius dialysis) to 2.4 ± 0.9 h (hemodialysis) and 2.0 ± 0.6 h (hemodiafiltration) (P < 0.01 for Genius dialysis versus hemodiafiltration). Prediction of steady-state conditions indicated that even with daily hemodialysis, SBECD will still exceed SBECD exposure of patients with normal renal function by a factor of 6.2. SBECD was effectively eliminated during 6 h of renal replacement therapy by all methods, using high-flux polysulfone membranes, whereas elimination of voriconazole was quantitatively insignificant. The SBECD half-life during renal replacement therapy was nearly normalized, but the average SBECD exposure during repeated administration is expected to be still increased.

Renal failure

2019 ◽  
pp. 547-560
Keyword(s):  
Palliative Care ◽  
Renal Failure ◽  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
Symptom Management ◽  
End Stage Renal Failure ◽  
Care Services ◽  
Palliative Care Services ◽  
End Stage

This chapter describes the issues associated with providing palliative care to patients with renal failure, and covers initiation of renal replacement therapy, conservative treatment, symptom management for patients with advanced renal disease, and issues surrounding stopping renal replacement therapy. As obesity and diabetes increase, so does the incidence of chronic renal disease and end-stage renal failure. Determining the exact number of patients dying of renal failure is challenging. Often the cause of death will be ascribed to an associated contributing factor, e.g. diabetes mellitus, or the final acute event resulting in death, e.g. myocardial infarction. However, we know that renal failure is an independent risk factor for cardiovascular disease and is associated with a high all-cause mortality.1 In addition, patients with end-stage renal failure have a significant symptom burden and therefore it is important that patients have access to palliative care services to assist with symptom management, advanced care planning, and, where appropriate, decisions around dialysis and transplantation.

scholarly journals Malignant tumors in patients with end stage renal failure undergoing renal replacement therapy

2012 ◽  
Vol 5 ◽  
pp. 382-387 ◽  
Author(s):  
Grzegorz Kade ◽  
Arkadiusz Lubas ◽  
Lubomir Bodnar ◽  
Cezary Szczylik ◽  
Zofia Wańkowicz
Keyword(s):  
Renal Failure ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Malignant Tumors ◽  
End Stage Renal Failure ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document